Ausgabe 4/2015
Inhalt (16 Artikel)
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations
- Myeloproliferative Disorders (C Harrison, Section Editor)
Xavier Cahu, Stefan N. Constantinescu
Current Challenges in Stem Cell Transplantation in Myelofibrosis
- Myeloproliferative Disorders (C Harrison, Section Editor)
Nicolaus Kröger
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis
- Myeloproliferative Disorders (C Harrison, Section Editor)
Jason Gotlib
Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis
- Myeloproliferative Disorders (C Harrison, Section Editor)
Giovanni Barosi
Immunological Consequences of JAK Inhibition: Friend or Foe?
- Myeloproliferative Disorders (C Harrison, Section Editor)
Donal P. McLornan, Alesia A. Khan, Claire N. Harrison
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
- Myeloproliferative Disorders (C Harrison, Section Editor)
Paola Guglielmelli, Giada Rotunno, Annalisa Pacilli, Alessandro Maria Vannucchi
Novel Induction Regimens in Multiple Myeloma
- Multiple Myeloma (R Nievszky, Section Editor)
Karie D. Runcie, Tomer M. Mark
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies
- Multiple Myeloma (R Nievszky, Section Editor)
Rebecca Karp Leaf, Hearn Jay Cho, David Avigan
Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider
- Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Michael A. Thompson, Navneet S. Majhail, William A. Wood, Miguel-Angel Perales, Mélanie Chaboissier
Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM
- Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Naveen Pemmaraju, Vikas Gupta, Ruben Mesa, Michael A. Thompson
Mature T-cell leukemias: Molecular and Clinical Aspects
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
Nathanael G. Bailey, Kojo S. J. Elenitoba-Johnson
Molecular Pathogenesis of Peripheral T Cell Lymphoma
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
Mamiko Sakata-Yanagimoto, Shigeru Chiba
Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
Jonathan Hebb, Holbrook Kohrt
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
Monica Bellei, Chadi Nabhan, Emanuela Anna Pesce, Luana Conte, Julie M. Vose, Francine Foss, Massimo Federico
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
A. A. Gru, B. H. Haverkos, A. G. Freud, J. Hastings, N. B. Nowacki, C. Barrionuevo, C. E. Vigil, R. Rochford, Y. Natkunam, R. A. Baiocchi, P. Porcu
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy
- T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
Catherine G. Chung, Brian Poligone
